Rare Disease Deal Benchmarks
Gene therapy, SMA, Duchenne, hemophilia, and orphan drug deal benchmarks. Benchmarks derived from 123 verified transactions.
123
Total Deals
$397M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
52
license
41
acquisition
21
collaboration
7
option
2
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Hanmi Pharm → Eli Lilly and Company sonefpeglutide | license | $75M | $1.2B | Jun 2026 |
Oscotec → Agios Pharmaceuticals cevidoplenib | license | $25M | — | Jun 2026 |
BioCryst Pharmaceuticals, Inc. → Neopharmed Gentili navenibart | license | $70M | $345M | May 2026 |
Dyno → Astellas muscle disorder capsid | license | $15M | — | Apr 2026 |
Dyno Therapeutics → Astellas muscle disorder capsid | license | $15M | — | Apr 2026 |
Soleno Therapeutics → Neurocrine Biosciences Vykat XR | acquisition | $2.9B | $2.9B | Apr 2026 |
Santhera → Nxera Agamree | license | $40M | $205M | Apr 2026 |
Regenxbio → Nippon Shinyaku rare disease gene therapy portfolio | license | $110M | $810M | Mar 2026 |
uniQure → CSL Hemgenix | license | $450M | $1.9B | Mar 2026 |
Inozyme Pharma → BioMarin Pharmaceutical Inozyme Pharma | acquisition | $270M | $270M | Jul 2025 |
Benchmark Your Rare Disease Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 123 verified rare disease transactions.
Run Rare Disease Benchmark